Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 542

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

Open access
Herman, Joseph M., Chang, Daniel T., Goodman, Karyn A., Dholakia, Avani S., Raman, Siva P., Hacker‐Prietz, Amy, Iacobuzio‐Donahue, Christine A., Griffith, Mary E., Pawlik, Timothy M., Pai, Jonathan S., O'Reilly, Eileen, Fisher, George A., Wild, Aaron T., Rosati, Lauren M., Zheng, Lei, Wolfgang, Christopher L., Laheru, Daniel A., Columbo, Laurie A., Sugar, Elizabeth A., Koong, Albert C.·2015·Cancer

Abstract

BACKGROUND: This phase 2 multi‐institutional study was designed to determine whether gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single‐fraction SBRT in patients with locally advanced pancreatic cancer (LAPC). METHODS: A total of 49 patients with LAPC received up to 3 doses of GEM (1000 mg/m 2 ) followed by a 1‐week break and SBRT (33.0 gray [Gy] in 5 fractions). After SBRT, patients continued to receive GEM until disease progression or toxicity. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0] and the Radiation Therapy Oncology Group radiation morbidity scoring criteria. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ‐C30) and pancreatic cancer‐specific QLQ‐PAN26 module before SBRT and at 4 weeks and 4 months after SBRT. RESULTS: The median follow‐up was 13.9 months (range, 3.9‐45.2 months). The median age of the patients was 67 years and 84% had tumors of the pancreatic head. Rates of acute and late (primary endpoint) grade ≥2 gastritis, fistula, enteritis, or ulcer toxicities were 2% and 11%, respectively. QLQ‐C30 global quality of life scores remained stable from baseline to after SBRT (67 at baseline, median change of 0 at both follow‐ups; P >.05 for both). Patients reported a significant improvement in pancreatic pain ( P = .001) 4 weeks after SBRT on the QLQ‐PAN26 questionnaire. The median plasma carbohydrate antigen 19‐9 (CA 19‐9) level was reduced after SBRT (median time after SBRT, 4.2 weeks; 220 U/mL vs 62 U/mL [ P <.001]). The median overall survival was 13.9 months (95% confidence interval, 10.2 months‐16.7 months). Freedom from local disease progression at 1 year was 78%. Four patients (8%) underwent margin‐negative and lymph node‐negative surgical resections. CONCLUSIONS: Fractionated SBRT with GEM results in minimal acute and late gastrointestinal toxicity. Future studies should incorporate SBRT with more aggressive multiagent chemotherapy. Cancer 2015;121:1128–1137 . © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29161

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 542

Metadata

Authors
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker‐Prietz, A., Iacobuzio‐Donahue, C. A., Griffith, M. E., Pawlik, T. M., Pai, J. S., O'Reilly, E., Fisher, G. A., Wild, A. T., Rosati, L. M., Zheng, L., Wolfgang, C. L., Laheru, D. A., Columbo, L. A., Sugar, E. A., & Koong, A. C.
Venue
Cancer
Publisher
Wiley
Published
2014-12-23
Volume
121
Issue
7
Pages
1128-1137
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1563283949
Cited by
542
References
26
FWCI
16.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. https://app.cochat.ai/papers/10.1002/cncr.29161
The paper
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker‐Prietz, A., Iacobuzio‐Donahue, C. A., Griffith, M. E., Pawlik, T. M., Pai, J. S., O'Reilly, E., Fisher, G. A., Wild, A. T., Rosati, L. M., Zheng, L., Wolfgang, C. L., Laheru, D. A., Columbo, L. A., Sugar, E. A., & Koong, A. C. (2015). Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. https://doi.org/10.1002/cncr.29161

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.